Postoperative Management of Recurrence After Radiosurgery and Surgical Resection for Brain Metastases and Predicting Benefit From Adjuvant Radiation
Practical Radiation Oncology · 2023
DOI: 10.1016/j.prro.2023.05.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Practical Radiation Oncology, 2023. Verfasst von Samantha M Buszek und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. Hauptthemen laut MEDLINE: Radiosurgery, Brain Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Stereotactic radiosurgery (SRS) is often used as upfront treatment for brain metastases. Progression or radionecrosis after SRS is common and can prompt resection. However, postoperative management strategies after resection for SRS failure vary widely, and no standard practice has been established. In this approved study, we retrospectively reviewed patients who received SRS for a brain metastasis followed by resection of the same lesion. We extracted patient-, disease-, and treatment-related variables and information on disease-related outcomes. Univariate and multivariate analyses of clinicopathologic variables were used to create a model to predict factors associated with local failure (LF). A total of 225 patients with brain metastases treated with SRS from 2009 to 2017 followed by surgical resection were identified. Overall, 65% of cases had gross total resection (GTR) on postoperative imaging review. Twenty-one patients (9.3%) received adjuvant radiation therapy to the surgical cavity, and 204 (90.7%) were observed. Of these 204 patients, 118 had GTR with evidence of tumor within the pathology specimen. With a median follow-up of 13 months after resection, 47 patients (40%) developed LF after surgery. After salvage resection of a brain metastasis initially treated with SRS, the observed LF rate was 40% among those who had a GTR and evidence of tumor on pathologic examination. This LF rate is sufficiently high that adjuvant radiation to the surgical bed after salvage resection should be considered in these cases when there is tumor in the pathology, even after a GTR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
- Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas.
- Department of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, Texas.
- Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: cchung3@mdanderson.org.
Zitieren
APA
Buszek, S. M., Tran, B., Long, J. P., Luo, D., Suki, D., Li, J., Ferguson, S., & Chung, C. (2023). Postoperative Management of Recurrence After Radiosurgery and Surgical Resection for Brain Metastases and Predicting Benefit From Adjuvant Radiation. Practical Radiation Oncology. https://doi.org/10.1016/j.prro.2023.05.010
Vancouver
Buszek SM, Tran B, Long JP, Luo D, Suki D, Li J, et al. Postoperative Management of Recurrence After Radiosurgery and Surgical Resection for Brain Metastases and Predicting Benefit From Adjuvant Radiation. Practical Radiation Oncology. 2023. doi:10.1016/j.prro.2023.05.010
BibTeX
@article{Buszek2023,
author = {Buszek, Samantha M and Tran, Benjamin and Long, James P and Luo, Dershan and Suki, Dima and Li, Jing and Ferguson, Sherise and Chung, Caroline},
title = {Postoperative Management of Recurrence After Radiosurgery and Surgical Resection for Brain Metastases and Predicting Benefit From Adjuvant Radiation},
journal = {Practical Radiation Oncology},
year = {2023},
doi = {10.1016/j.prro.2023.05.010}
}
EUVIMED